Vystar Corp. (OTC: VYST) is making a strong move up the charts and investors are starting to take notice. Breaking its previous highs on Friday VYST is emerging as a top traded stock in small caps.
VYST has been getting noticed for its Rx3000 ultraviolet (UV)-light air purification system designed specifically for hospitals which they acquired in 2018. The Company recently said it has shifted to Massachusetts production. Rx3000 utilizes ultraviolet-C (UV-C) germicidal irradiation (UVGI) to inactivate 99.97% of airborne viruses, bacteria and other pathogens on first pass.
Vystar Corp. (OTC: VYST) is a holding company for eco-friendly solutions for complex environmental challenges and the exclusive creator of Vytex Natural Rubber Latex (NRL), a multi-patented, all-natural, raw material that contains significantly reduced levels of the proteins found in natural rubber latex and can be used in over 40,000 products, and the owner of RxAir UV light air purification products. Vytex NRL is a 100% renewable resource, environmentally safe, “green” and fully biodegradable. Vystar is working with manufacturers across a broad range of consumer and medical products bringing Vytex NRL to market in adhesives, gloves, balloons, condoms, other medical devices and natural rubber latex foam mattresses, toppers, and pillows.
RxAir promotes a healthy lifestyle through the use of its innovative patented, ViraTech air purification technology, thereby improving the quality of life of each and every customer. Independently tested by EPA- and FDA-certified laboratories, the RxAir has been proven to destroy greater than 99% of bacteria and viruses and reduce concentrations of odors and VOCs. The RxAir uses high-intensity germicidal UV lamps that destroy bacteria and viruses instead of just trapping them, setting it apart from ordinary air filtration units. RxAir® and ViraTech® are registered trademarks of Vystar Corp.
To Find out the inside Scoop on VYST Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
As stated in May VYST shifted to Massachusetts production of its Rx3000®. The Rx3000 combines patented ViraTech™ germicidal UV-C light with a five-stage HEPA filtration proven in independent EPA- and FDA-certified laboratory testing to inactivate on first pass more than 99.97% of airborne viruses, bacteria and other contaminants. Rx3000 has been proven effective at inactivating airborne pathogens that cause pneumonia, influenza, MRSA (staph), streptococcus (whooping cough), tuberculosis (TB), measles and a myriad of other antibiotic-resistant and viral infections.
According to VYST press release Rx3000 is used in hundreds of hospitals and healthcare facilities. With an MSRP of $8,000 per unit to service a 1,500 – 3,000 sq. ft. area, Rx3000 is very cost effective. Vystar acquired 100% of the assets and patented intellectual property related to the Rx3000, RxAir™ for residential and small business use, custom filtration and other UV light air purification technologies from UV Flu Technologies (OTCBB: UVFT) in 2018. Vystar also acquired all of the equipment necessary to make the custom filters used in the Rx3000. These large multi-stage filters retail for approximately $800 and last up to 1 year, depending on use.
“We are proud to say that we’ve resumed production of the RX3000 and it is now made in Worcester, Massachusetts, enabling more control over quality and distribution,” stated Steve Rotman, CEO of Vystar. “We are now producing 50 units per week. Once we finish testing these units, we plan to ramp up to 1500 units.”
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $46 million market valuation VYST is reporting OTCQB with $10 million in current liabilities and over $6 million in sales during the last reporting quarter. The Company is currently delinquent in their filings. VYST is an exciting story developing in small caps; its 100% owned Rx3000 is FDA cleared as a Class II Medical Device and was designed by biomedical engineers for use in hospitals and healthcare facilities. Rx3000 utilizes ultraviolet-C (UV-C) germicidal irradiation (UVGI) to inactivate 99.97% of airborne viruses, bacteria and other pathogens on first pass. According to VYST press release Rx3000 is used in hundreds of hospitals and healthcare facilities. With an MSRP of $8,000 per unit. We will be updating on VYST when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with VYST.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in VYST either long or short and we have not been compensated for this article.